Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPRA-HF Extension
NCT07576257Phase 2Not yet recruiting
- Sponsor
- Sahlgrenska University Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, randomised, double-blind trial of sodium zirconium cyclosilicate in heart failure (HF) (2 arms), sponsored by Sahlgrenska University Hospital. Primary endpoints: Percentage of patients optimizing MRA therapy at 6 months and Efficacy of SZC on optimizing MRA in HF at 6 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07576257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07576257.